Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1745-6215
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Effectiveness of TOcilizumab in comparison to Prednisone In Rheumatoid Arthritis patients with insufficient response to disease-modifying antirheumatic drugs (TOPIRA): study protocol for a pragmatic trial ; volume:21 ; number:1 ; day:5 ; month:4 ; year:2020 ; pages:1-11 ; date:12.2020
Trials ; 21, Heft 1 (5.4.2020), 1-11, 12.2020
- Creator
-
Leeuw, Matthijs S. van der
Welsing, Paco M. J.
Hair, Maria J. H. de
Jacobs, Johannes W. G.
Marijnissen, Anne C. A.
Linn-Rasker, Suzanne P.
Fodili, Faouzia
Bos, Reinhard
Tekstra, Janneke
Laar, Jacob M. van
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s13063-020-04260-y
- URN
-
urn:nbn:de:101:1-2020062202263003386402
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:44 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Leeuw, Matthijs S. van der
- Welsing, Paco M. J.
- Hair, Maria J. H. de
- Jacobs, Johannes W. G.
- Marijnissen, Anne C. A.
- Linn-Rasker, Suzanne P.
- Fodili, Faouzia
- Bos, Reinhard
- Tekstra, Janneke
- Laar, Jacob M. van
- SpringerLink (Online service)
Other Objects (12)
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids
Effect of disease-modifying anti-rheumatic drugs on bone structure and strength in psoriatic arthritis patients
The sequence of disease-modifying anti-rheumatic drugs: pathways to and predictors of tocilizumab monotherapy
Systematic review of disease-modifying antirheumatic drugs for juvenile idiopathic arthritis
Utilizing biologic disease-modifying anti-rheumatic treatment sequences to subphenotype rheumatoid arthritis
Oral Conventional Synthetic Disease-Modifying Antirheumatic Drugs with Antineoplastic Potential: a Review
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns Among Rheumatologists in Europe and Japan
Real-World Persistence with Tocilizumab Compared to Other Subcutaneous Biologic Disease-Modifying Antirheumatic Drugs Among Patients with Rheumatoid Arthritis Switching from Another Biologic
Biologic Disease-Modifying Antirheumatic Drug Prescription Patterns for Rheumatoid Arthritis Among United States Physicians
Persistence with Biological Disease-modifying Antirheumatic Drugs and Its Associated Resource Utilization and Costs
Machine Learning Prediction of Treatment Response to Biological Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
Safety and Efficacy of Baricitinib in Patients Receiving Conventional Synthetic Disease-Modifying Antirheumatic Drugs or Corticosteroids